Indaptus Therapeutics (NASDAQ:INDP) (NASDAQ:INDP) is a clinical-stage biotechnology company focused on the development of novel immunotherapies to treat cancer, autoimmune diseases and transplant rejection. Headquartered in San Diego, California, Indaptus leverages proprietary protein engineering and cell therapy platforms to create targeted biologics designed to modulate both innate and adaptive immune responses. The company was founded in 2017 and has since expanded its research operations to include facilities in the U.S. and collaborations with academic centers in Europe.
At the core of Indaptus’s pipeline is a versatile cytokine prodrug platform engineered to deliver potent immune modulators selectively to sites of disease, thereby minimizing systemic toxicity. The company’s lead candidate, INDP-001, is a masked interleukin-2 derivative designed to activate natural killer (NK) cells and cytotoxic T lymphocytes within the tumor microenvironment. Preclinical studies have demonstrated that INDP-001 enhances the antitumor activity of adoptively transferred cell therapies while preserving safety margins observed with conventional cytokine treatments.
In addition to its cytokine prodrug technology, Indaptus is developing a proprietary lymphodepletion agent, INDP-002, aimed at improving the efficacy of CAR-T and NK cell therapies by creating a more favorable immunological niche for infused cells. Early-stage programs in the company’s pipeline include IND-006, an immunomodulatory fusion protein targeting autoimmune pathways in rheumatoid arthritis, and IND-007, a next-generation checkpoint agonist for solid tumors. These programs underscore Indaptus’s ambition to address both oncology and immunological disorders through novel mechanisms of action.
Leadership at Indaptus includes Chief Executive Officer David J. Smith, PhD, whose 20-year career spans senior roles at several biotech firms, and Chief Scientific Officer Maria L. Chen, PhD, an expert in cytokine biology. The company’s board features industry veterans with experience in drug development, regulatory affairs and strategic partnerships. Indaptus maintains collaborations with leading research institutions and patient advocacy groups, and it is positioned to advance multiple candidates toward human trials while exploring strategic alliances to accelerate commercialization.
